logo
Products
Technologies
Applications
Services
Resources
Selection Guides
About
APC Anti-human CD3 Antibody
HIT3b
The HIT3b monoclonal antibody binds to human CD3e, a 20 kD single-pass type i membrane protein commonly located on the surface of nkt cells, tregs, thymocytes (differentiation dependent)s, thymocytes and t cells. In many organisms, CD3 positively regulates T cell anergy, is a promoter of peptidyl-tyrosine phosphorylation and enhances interferon-gamma production. Also, it is a component of vital cellular pathways, namely, the G protein-coupled receptor signaling pathway, cell surface receptor signaling pathway and negative regulation of smoothened signaling pathway. From a research standpoint, it is of biological interest due to its association with vital macromolecules/ligands such as TCR. CD3 is a very popular antibody target, with over 80000 publications in the last decade. CD3e is frequently used in flow cytometry applications as a phenotypic marker for differentiation of cell types, particularly in the study of immunology. This antibody was purified through affinity chromatography and conjugated to APC (ex/em = 651/660 nm). It is compatible with the 642 nm laser and 664/20 nm bandpass filter (for example, as in the Luminex Guava easyCyte).
product image
product image
CatalogSize
Price
Quantity
100311C025 tests
Price
100311C1100 tests
Price
100311C2500 tests
Price
 
Antibody properties

Other namesT3E
CloneHIT3b
Hostmouse
Isotypemouse IgG1
Reactivityhuman
Spectral properties

Correction factor (280 nm)0.195
Extinction coefficient (cm -1 M -1)
730000
Excitation (nm)651
Emission (nm)660
Storage, safety and handling

H-phraseH303, H313, H333
Hazard symbolXN
Intended useResearch Use Only (RUO)
R-phraseR20, R21, R22
Contact us

Telephone
Fax
Emailsales@aatbio.com
InternationalSee distributors
Bulk requestInquire
Custom sizeInquire
Technical SupportContact us
Request quotationRequest
Purchase orderSend to sales@aatbio.com
ShippingStandard overnight for United States, inquire for international
Page updated on October 18, 2025